Acute Myeloid Leukemia (AML)

AAMDSIF Supports the Accelerating Kids' Access to Care Act

Original Publication Date
Article Source
Coalition Action
AAMDSIF Supports the Accelerating Kids' Access to Care Act. On March 26, 2025, AAMDSIF joined with 212 additional patient advocacy and medical center organizations in urging members of the US Congress to pass the Accelerating Kids’ Access to Care Act. Passage of this bill will…

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the

Original Publication Date
Article Source
External Web Content
ABSTRACT Patients (pts) with myelodysplasia-related AML (MR-AML) are now genetically recategorized, with three different groups in the International Consensus Classification: AML with mutated TP53 (TP53-AML), with myelodysplasia-related gene mutations (MR-GM AML), and with…

How I treat secondary acute myeloid leukemia

Original Publication Date
Article Source
External Web Content
Abstract Secondary acute myeloid leukemia (sAML) has traditionally been used to designate any AML disease arising from an antecedent hematologic disorder or after prior cytotoxic or radiation therapy. We now know sAML comprises multiple disease entities with distinct clinical and…

How I use maintenance therapy in acute myeloid leukemia

Original Publication Date
Article Source
External Web Content
Abstract Outcomes for acute myeloid leukemia (AML) have improved significantly in the past decade with the approval of novel therapeutics targeting diverse vulnerabilities of leukemic cells, expanded access to stem cell transplantation, and improved safety of transplantation…

Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

Original Publication Date
Article Source
External Web Content
Dear Editor, Secondary acute myeloid leukemia (sAML), a subset of AML, may arise from antecedent hematologic disorders (antecedent myelodysplastic syndrome or chronic myelomonocytic leukemia [A-MDS/CMML]) or complication of prior cytotoxic chemotherapy or radiation therapy…

2025 AAMDSIF Bone Marrow Failure Summit Acute Myeloid Leukemia Expert Panel

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
Presenter(s)
Mikkael Sekeres, MD, MS
Kah Poh (Melissa) Loh, MBBCh BAO, MS, FACCC
Christopher Hourigan, DM, DPhil, FRCP
Noa Holtzman, MD
Watch AML experts at the 2025 AAMDSIF Bone Marrow Failure Summit translate and discuss the latest science to advance patient outcomes. This session is moderated by Mikkael Sekeres, MD, MS from the University of Miami. Session Topics: HMA + Ven vs. 7+3 vs. liposomal cytarabine…

Maintenance Therapy in AML: What Is the Future Potential?

Original Publication Date
Article Source
External Web Content
ABSTRACT Over the last decade, there have been significant advancements in the treatment for patients with acute myeloid leukemia (AML) including the addition of novel, targeted agents to intensive or nonintensive chemotherapy regimens. However, despite this, the majority of…

Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia

Original Publication Date
Article Source
External Web Content
Significant progress in the characterization of molecular pathogenic events in acute myeloid leukemia (AML) has led to better characterization of prognosis and identification of subsets that are more likely to benefit from currently available strategies. Furthermore, deciphering…
Subscribe to Acute Myeloid Leukemia (AML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.